II.1 CCR Reportability Guide

Please refer to the reportability guide below for information on specific histologies and sites for tumors that are reportable or not reportable to the CCR.

 

California Cancer Registry Reportability Guide

REPORTABLE TERMS

Ambiguous Terminology

Considered as Diagnostic of Cancer

Exception: If the cytology is reported as “suspicious” and neither a positive biopsy nor a physician’s clinical impression supports the cytology findings, do not consider as diagnosis of cancer.

Apparent(ly)  

Appears to   

Comparable with

Compatible with

Consistent with

Favor (s)

Malignant appearing

Most likely

Presumed

Probable

Suspect (ed)

Suspicious (for)

Typical (of)

The reportable terms noted above are used ONLY for reportability. These are not to be used for determining tumor extension/involvement or for determining histological classification. There are separate lists for those.

SITE SPECIFIC REPORTABILITY GUIDE

Site

Histology

Reference

Reportable/Non-reportable Criteria

SKIN

C44.0-C44.9

8000-8110

Volume One: Skin Reportability

Has always been non-reportable

  • Basal cell carcinomas of the skin

  • Epithelial carcinomas of the skin

  • Papillary carcinomas of the skin

  • Squamous cell carcinomas of the skin

  • Early melanoma  

  • Evolving melanoma

EXCEPTIONS: Reportable skin cancers include:

  • Skin cancers in the genital sites (any histology): (vagina (C52.9); clitoris (C51.2); labium (C51.0); vulva (C51.9); prepuce (C60.0); penis (C60.9) and scrotum (C63.2) are reportable.

  • All other malignant tumors of the skin, such as adnexal carcinomas (e.g., carcinomas of the sweat gland, sebaceous gland, ceruminous gland, and hair follicle), adenocarcinomas, lymphomas, melanomas, sarcomas, and Merkel cell tumors are reportable regardless of site. Any carcinoma arising in a hemorrhoid is reportable since hemorrhoids arise in mucosa, not in skin.

  • “Early melanoma in situ” and “Evolving melanoma in situ” NOTE: These terms must be stated exactly as stated here. In "in situ” behavior must be included in the diagnosis in order for these to be reportable.  No variation in terms allowed.

CERVIX

C53.0-C53.9

Any morphology

with behavior 2

Volume One: Definition of Cancer

Reportable = Before 1996

  • Carcinoma in situ of the cervix (CIS) (including squamous cell & adenocarcinoma).

  • Cervical Intraepithelial Neoplasia grade III (CIN III).

  • Cervical Intraepithelial Neoplasia with severe dysplasia (CIN III).

BENIGN BRAIN (NOTE: Benign Schwannoma section below)

C70.0-70.9

C71.0-71.9

C72.0-C72.9

C75.1-C75.3

Behavior = 0 or 1

Volume One: Benign/Borderline Brain and CNS Tumors

Reportable = 2001+

Hemangioma, NOS and cavernous hemangiomas (9120/0 or 9121/0)

SEER Program Manual

SEER INQ #20130001

Reportable = 2001+

Standard Setter Differences:

  • CCR reportability date for benign brain tumors is 2001. This included benign schwannoma’s. In 2004 benign brain tumors (including schwannoma’s) became required for collection by SEER and CDC registries as well.

  • Juvenile astrocytoma is coded as borderline in ICD-O-3; North America registries report as 9421/3. (per ICD-O-3 Errata dated 5/22/2001)

BENIGN SCHWANNOMAS

C72.2-72.5

9560

Behavior=0

SEER and CDC

Reportable = 2004+ (only report site codes C72.2-72.5)

C72.0

9560

Behavior=0

SEER SINQ #20130023

Reportable = 2011+ (expanded to include site code C72.0)

Per SEER instruction, we are to report benign schwannomas (9560/0) of the spinal cord (C72.0) and of the cranial nerves (C72.2 - C72.5); therefore, these are both reportable to the CCR.  Benign schwannomas occurring anywhere else such as the peripheral nerves or spinal nerves are not reportable to the CCR.        

BORDERLINE OVARIAN

C56.9

8442/1

8451/1

8462/1

8472/1

8473/1

Volume One: Borderline Ovarian Tumors

Non-reportable = 2016+

Reportable = behavior /3 pre-2001 or behavior /1 for 2001-2015

INTRAEPITHELIAL NEOPLASIA NOTE: (8077/2 and 8148/2) must be stated exactly as stated here. Grade III must be included in the diagnosis in order for these to be reportable. No variation in terms allowed.

AIN III (anal intraepithelial neoplasia, Grade III or 3)

C21.0

C21.1

8077/2, Grade III

Volume One: In Situ Coding

DSQC Memo #2001-03

DSQC Memo #2002-01

PAQC Memo #2012-03

Reportable = 2001+

DIN III (ductal intraepithelial neoplasia, Grade III or 3)

C50.   

8500/2, Grade III

Volume One: In Situ Coding

Coding

DSQC Memo #2002-01

Reportable = 2001+

LIN III (laryngeal intraepithelial neoplasia, Grade III or 3)

C32.    

8077/2, Grade III

Volume One: In Situ Coding

DSQC Memo #2002-01

Reportable = 2001+

LN III (breast lobular neoplasia, Grade III or 3)

LIN III (breast lobular intraepithelial neoplasia, Grade III or 3)

C50.    

8500/2, Grade III

Volume One: In Situ Coding

SEER Program Manual

Reportable = 2016+

PanIN-III (pancreatic intraepithelial neoplasia, Grade III or 3)

C25.    

8500/2, Grade III

Volume One: In Situ Coding

Reportable = 2004+

PeIN III (penile intraepithelial neoplasia, Grade III or 3)

C60._

8077/2, Grade III

8148/2, Grade III

Volume One: In Situ Coding

Reportable = 2001+

PIN III (prostatic intraepithelial neoplasia, Grade III or 3)

C61.9

8148/2, Grade III

Volume One: In Situ Coding

Has never been reportable to the CCR

SIN III (squamous intraepithelial neoplasia, Grade III or 3)

All sites (Excluding Cervix)

8077/2, Grade III

Volume One: In Situ Coding

SEER Program Manual

Reportable = 2014+

VAIN III (vaginal intraepithelial neoplasia, Grade III or 3)

VIN III  (vulvar intraepithelial neoplasia, Grade III or 3)

C52._

C51._

8077/2, Grade III

Volume One: In Situ Coding

DSQC Memo #2002-01

PAQC Memo #2012-03

Reportable = 1992+

LYMPHATIC & HEMATOPOIETIC DISEASES---SUBSEQUENT DIAGNOSES

The reportable terms noted above are used ONLY for solid tumors. For reportability rules of hematopoietic and lymphoid neoplasms, refer to the Hematopoietic and Lymphoid Neoplasm Database and Coding Manual.

DATE DIAGNOSIS YEAR

1st Primary

2nd primary

Reference

Prior to 2001

Prior to 2001

SEER Hematopoietic Manual & Database

2001--2009

2001--2009

ICD-O-3 table in Volume I, Appendix R

SEER Hematopoietic Manual & Database

Prior to 2001

2001-2009

ICD-O-3 table in Volume I, Appendix R

SEER Hematopoietic Manual & Database

2010

2010

SEER Hematopoietic Manual & Database

Prior to 2010

2010

SEER Hematopoietic Manual & Database

 

Clarification on Reportability

Carcinoid tumors, NOS of the Appendix (C18.1)  

8240/3 effective with 2015

 

8240/1 is obsolete in 2015

ICD-O-3 Updates 2015  

SEER Program Manual- Reportability  

Reportable = 2015 +  

Dysplasia (severe, high grade)

Only reportable when it is specified as carcinoma in situ or pathologist documents as being synonymous with carcinoma in situ.

GIST – Gastrointestinal stromal tumors

Only reportable if identified as being in situ; is identified as malignant on the pathology report; or the patient is undergoing treatment as if it is malignant. SEER SINQ #20140088

Liver

Report liver cases with an LR-5 or LR-5V based on the 2014 American College of Radiology Definitions, http://nrdr.acr.org/lirads       

                                              

Do not report liver cases based only on an LI-RADS category of LR-4.

Lymphoma In situ   

SEER Hematopoietic Manual & Database

SEER SINQ #20130042

Has always been non-reportable  

PUNLMP – Papillary Urothelial Neoplasm of low malignant potential

Not reportable. Pre malignant growths in the upper urinary tract (renal pelvis, ureters, urinary bladder part of urethra).

Pancreas (C25.0-C25.9)

Neuroendocrine tumor when dx is insulinoma (8240/3 or 8151/3)

 

Cystic pancreatic endocrine neoplasm (CPEN) (8150/3)

 

Cystic pancreatic endocrine neoplasm specified as neuroendocrine tumor, Grade 1 (8240/3)

 

Cystic pancreatic endocrine neoplasm specified as neuroendocrine tumor, Grade 2 (8249/3)

 

Solid pseudopapillary neoplasm of pancreas (8452/3)

 

Non-invasive mucinous cystic neoplasm (MCN) of pancreas with high grade dysplasia (8470/2)

 

NOTE: Term high-grade dysplasia replaces term mucinous cystadenocarcinoma, non-invasive  

Reportable = 2015 +  

Pituitary Gland (C75.1)  

 

Rathke pouch tumor (9350/1)

 

NOTE: Rathke cleft cyst and Rathke pouch tumor are different conditions. Rathke cleft cyst is not reportable.  

Reportable = 2001 +

Testes (C62.0-C62.9)

Mature teratoma of testes in adult

 

Adult defined as post puberty

 

NOTE: Do not report if it is unknown whether patient is pre or post pubescence.  

 Reportable = 2015 +

Urine cytology - Positive for malignancy

SEER Program Manual- Reportability  

SEER INQ #20120079

Volume  One: Ambiguous Diagnostic Reportable Terms 

Reportable = 2013 +

Venous angioma /Venous hemangioma

Venous angiomas are NOT reportable wherever they arise.  The primary site for venous hemangioma arising in the brain is blood vessel (C490). The combination of 9122/0 (Venous hemangioma) and C490 is not reportable.

 

NOTE:  This is a venous abnormality, previously referred to as venous angiomas and currently referred to as developmental venous anomalies (DVA)

 

 

<< Prev.       Next >>